Anticoagulation Agents
Phase 3Small molecule
Anticoagulation Agents is one of 81 small molecule programs targeting Anticoagulation. It is currently in Phase 3.
5
Indications
7
Total Trials
3
Active Trials
80
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
137 competitors in Atrial Fibrillation
#DrugCompanyPhaseTrials
1Anticoagulation Agents
IInari Medical
Phase 3
Calquence
AstraZenecaPreclinical
Rituxan
RochePreclinical
Coumadin
AAbbott
Preclinical
Brukinsa
BBeOne Medicines
Preclinical
Imbruvica
PPharmacyclics LLC.
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Ondexxya
UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
Preclinical
Romazicon
CConrado Roberto Hoffmann Filho
Preclinical
Statin
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Venous thrombosis1 trial
Atrial Fibrillation1 trial
2 more indications
Anticoagulation1 trial
Early Versus Late Initiation of Anticoagulation in Mild-to-moderate AIS Patients With NVAF
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT06057467·2,351 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anticoagulation Agents. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- IInari Medical